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DIAGNOSIS
Subpectoralis abscess due to group B b-hemolytic
streptococcus (Streptococcus agalactiae) (GBS).
DISCUSSION
1. The clinical presentation of GBS infections in
non-pregnant adults includes primary bacteremia,
followed by skin and soft tissue infection (celluli-
tis, surgical or burn wounds, ulcers and abscesses)
[1,2,5–8]. Our patient had a subpectoral abscess
and an underlying connective tissue disease. The
presence of a chest wall abscess due to GBS is
exceptional [1,3,4,7], and has been reported only in
recent years, in one case [1]. One or more con-
ditions predisposing to infection can be identiﬁed
in most adults suffering from invasive disease
(diabetes mellitus, cancer, liver disease). Con-
nective tissue diseases are exceptional predispos-
ing causes [1,5–8,10]. Thus, only systemic lupus
erythematosus [9–11] and rheumatoid arthritis
[7,9,10] have been reported as underlying medical
conditions. Undifferentiated connective tissue dis-
ease has not been reported before as an underlying
disease in adults with invasive GBS infection.
2. The ﬁrst step in identifying this bacterium
requires observation of b-hemolysis on the blood
agarplate,whichappearsascompleteclearing(lysis
of erythrocytes) of the blood. While most bacteria
are non-b-hemolytic, Streptococcus (Streptococcus
pyogenes; S. agalactiae; certain streptococci included
in the S. viridans group, such as S. anginosus groups
and S. mutans; S. dysgalactiae subsp. equisimilis; S.
porcinus; and S. iniae), Staphylococcus, Enterococcus
(Enterococcus durans), Listeria monocytogenes, Bacil-
lus cereus and some Enterobacteriaceae are b-
hemolytic in sheep blood agar. B. anthracis is
non-hemolytic or very weakly hemolytic.
The second step involves recognition of the
organism’s morphology (coccus or rod) by
Gram-staining of the colony. The catalase reaction
is also helpful in distinguishing Gram-positive
cocci (streptococci and enterococci are catalase
negative). Small, grayish, catalase-negative, b-
hemolytic colonies suggest GBS.
The third step involves identifying the b-hemo-
lytic streptococci using traditional phenotypic cri-
teria [Lanceﬁeld serologic grouping and the
CAMP test (a lytic phenomenon produced by
the synergistic action of a beta hemolysin of S.
aureus and the CAMP factor of group B strepto-
cocci as was deﬁned originally by christie, Atkins
and Munchen-Petersen)]. In our experience, rapid
antigen extraction and agglutination directly
from the colonies (Slidex Strepto-Kit; BioMe´rieux,
Durham, NC, USA) is very useful, especially for
identifying groups A and B; it is less reliable for
groups C, D, F and G. Streptococcus suis, Strepto-
coccus porcinus, Streptococcus iniae and some Strep-
tococcus anginosus groups do not agglutinate with
Lanceﬁeld antibodies.
Finally, a susceptibility test with selected anti-
biotics helps to clarify the identity of the micro-
organism. In this case, the GBS was susceptible to
penicillin, erythromycin, vancomycin, cefotaxime,
clindamycin, and oxacillin.
3. Therapy with penicillin G for a minimum of
14 days and surgery (incision and drainage of
abscesses when needed, or debridement of devi-
talized tissue) are recommended for the treatment
of soft tissue infections due to GBS [1,12]. GBS iso-
lates remainuniformlysusceptible topenicillin, am-
picillin, cephalosporins [12,13], excluding cefoxitin
[12], vancomycin, teicoplanin, and carbapenems
[12,13]. Some isolateswith intermediate susceptibil-
ity to penicillin and cephalosporins have been
reported [7,14–16], as well as some strains with
vancomycin MICs up to 4mg/L [14,16] and imipe-
nemMICsupto2mg/L[14]. Inour institution,since
1989, all isolates of GBS have been susceptible to
penicillin, ampicillin, cephalothin, cefotaxime, and
vancomycin, but erythromycin resistance increased
from 5% in 1989 to 9% in 2000.
The breakpoint of in vitro susceptibility of peni-
cillinase-resistant penicillins (PRPs), which corre-
lates with the successful treatment of streptococcal
infections, has not been determined. Although
PRPs are active in vitro against streptococci, their
MICs for thesemicroorganisms are higher than the
MICs of penicillin G [17]. The oxacillin MIC for
GBS varies from 0.04 to 0.8mg/L [18], and the
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mean MIC is 0.06mg/L [17], so antibacterial activ-
ity should be high enough to eradicate most strep-
tococci. Our patient had an invasive GBS infection.
The GBS MIC for oxacillin was 1mg/L, but the
patient continued to have fever and chest pain
despite therapy with oral cloxacillin, and a change
in therapy was needed. We do not know whether
parenteral cloxacillin would have improved the
response of the patient.
Although penicillin and ampicillin are the drugs
of choice for the treatment of GBS infection, the in
vitro activities of PRPs, cephalosporins, carbape-
nem and vancomycin suggest that these agents
might be used for the successful treatment of
serious invasive GBS infections. More studies
are necessary to deﬁne fully the efﬁcacy of agents
other than ampicillin and penicillin G in the treat-
ment of patients with invasive GBS disease.
GBS strains are uniformly resistant to co-trimox-
azole and aminoglycosides [12], but the latter can
be used as synergistic therapy with penicillin for
the treatment of endocarditis [12] and infection
caused by a penicillin-tolerant microorganism
[14]. The clinical importance of this phenomenon
is unknown [12,14].
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